HAWK Biosystems proudly announces that its founder, Professor Peter J. Parker, has received the Entrepreneurship Recognition Award from Cancer Research Horizons (CRH) during a gala dinner held in recognition of visionary scientific innovation and translational impact.
The award from CRH – the innovation arm of Cancer Research UK – highlights individuals who have demonstrated exceptional leadership in turning scientific insight into practical solutions with commercial and clinical impact.
Professor Parker, an internationally renowned cancer biologist and founder of HAWK Biosystems, was celebrated for his outstanding contributions to cancer research and entrepreneurship. His pioneering work on protein kinase C and related signalling pathways has helped lay the foundation for many of today’s targeted cancer therapies. In addition to his scientific achievements, Prof. Parker has been a leading force in translating research discoveries into real-world solutions that benefit patients.
Throughout his distinguished career, he has held senior leadership positions at the Francis Crick Institute, the Medical Research Council (MRC), and King’s College London, where he has led efforts to turn fundamental discoveries into tangible patient outcomes. His dedication to mentorship and enterprise has inspired a new generation of translational researchers.
“We are deeply proud of Professor Parker’s recognition by Cancer Research Horizons,” said Fernando Aguirre, CEO at HAWK Biosystems. “This award reflects not only his groundbreaking science but also his enduring commitment to making cancer research matter for patients.”
HAWK Biosystems congratulates Professor Parker on this well-deserved honour and remains committed to advancing his legacy of innovation through technologies like QF-Pro®, which enable deeper insight into cancer biology and therapy response.
